Search
01/01/2025
Prospective View of Emicizumab Treatment According Thrombin Generation Time
Vilalta, N, Triquell, M, Llobet, D, Simón, M, Cerdà, N, Carrasco, M, Mateo, J. Prospective View of Emicizumab Treatment According Thrombin Generation Time. HAEMOPHILIA. 2025; 31DOI:. PMID:. IF:3.000(Q2/4D).
01/01/2025
Probiotics: A Potential Strategy for Preventing and Managing Cardiovascular Disease
López-Yerena, A, Villaplana, VD, Badimon, L, Vilahur, G, Padro, T. Probiotics: A Potential Strategy for Preventing and Managing Cardiovascular Disease. Nutrients. 2025; 17(1)DOI:10.3390/nu17010052. PMID:39796486. IF:5.000(Q1/2D).
01/01/2025
Effectiveness and safety of insulin glargine 300 U/mL in insulin-naïve individuals according to diabetes duration: Results from the REALI European pooled data analysis
Gourdy, P, Bonadonna, RC, Mauricio, D, Müller-Wieland, D, Mauquoi, C, Vera, C, Bonnemaire, M, Freemantle, N. Effectiveness and safety of insulin glargine 300 U/mL in insulin-naïve individuals according to diabetes duration: Results from the REALI European pooled data analysis. DIABETES OBESITY & METABOLISM. 2025; 27(1)DOI:10.1111/dom.16008. PMID:39420531. IF:5.700(Q1/2D).
01/01/2025
Ileal Predominance in Crohn's Disease Is Associated With Increased Intestinal Surgery and Biological Therapy Use, With Lower Treatment Persistence
Giordano, A, Pérez-Martínez, I, Gisbert, JP, Ricart, E, Martín-Arranz, MD, Mesonero, F, Parga, MLD, Rivero, M, Iglesias, E, Fernández-Prada, S, Calafat, M, Villarino, MTA, Turrión, MAD, Hernández-Camba, A, Lidón, RV, Carpio, D, Brunet, E, Moranta, FR, García, LA, Cuquerella, JT, Bermejo, F, Madero, L, Esteve, M, González-Muñoza, C, Martínez-Montiel, P, Huguet, JM, Calle, JLP, Rodríguez-Lago, I, Ausín, MS, Poyatos, RHL, García-Bosch, O, Marín, GS, Taxonera, C, Ponferrada-Diaz, A, Barreiro-de Acosta, M, Bujanda, L, Serra, RB, Ramos, L, Vera, I, Abizanda, ES, Piqueras, M, Gómez, CS, García-Sepulcre, MF, Arregui, MV, Murillo, NR, Llaó, J, Lucendo, AJ, Marín-Jiménez, I, Camps-Aler, B, Villafranca, CM, Ceballos, D, Ver, Y, Fernández-Salazar, LI, Alcaín, G, Valldosera, G, Andrés, PR, Martínez-Flores, C, Coronel, AF, Ginard, D, García, L, Gomez, IB, Argueelles-Arias, F, Miyashiro, EI, de la Piscina, PR, Villalba, LH, Notari, PA, Martínez-Pérez, TD, Fernández, H, Gilabert, P, Rosas, CM, Nos, P, Gil, JL, López, VMN, Muñoz, F, Palomares, MTDL, Lucio, AS, Merino, O, de Prado, IN, Leal, C, de Carpi, JM, Sánchez, LB, Arce, NM, Frago, S, Mateu, BB, Domènech, E, Planella, EG. Ileal Predominance in Crohn's Disease Is Associated With Increased Intestinal Surgery and Biological Therapy Use, With Lower Treatment Persistence. AMERICAN JOURNAL OF GASTROENTEROLOGY. 2025; 120(1)DOI:10.14309/ajg.0000000000003207. PMID:39745305. IF:7.600(Q1/1D).
01/01/2025
Vitamin D Supplementation Is Associated with Inflammation Amelioration and Cognitive Improvement in Decompensated Patients with Cirrhosis
Diaz-Ruiz, R, Poca, M, Roman, E, Panadero-Gomez, R, Cuyàs, B, Bañares, I, Morales, A, Puerto, M, Lopez-Esteban, R, Blazquez, E, Fernández-Castillo, M, Correa-Rocha, R, Rapado-Castro, M, Breton, I, Bañares, R, Soriano, G, Garcia-Martinez, R. Vitamin D Supplementation Is Associated with Inflammation Amelioration and Cognitive Improvement in Decompensated Patients with Cirrhosis. Nutrients. 2025; 17(2)DOI:10.3390/nu17020226. PMID:39861356. IF:5.000(Q1/2D).
01/01/2025
Real-World Experience of Imipenem-Relebactam Treatment as Salvage Therapy in Difficult-to-Treat Pseudomonas aeruginosa Infections (IMRECOR Study)
Machuca, I, Dominguez, A, Amaya, R, Arjona, C, Gracia-Ahufinger, I, Carralon, M, Giron, R, Gea, I, De Benito, N, Martin, A, Galan, F, Martinez, JA, Iglesias, R, Revuelto, J, Caston, JJ, Cano, A, Ruiz-Arabi, E, Martínez-Martínez, L, Torre-Cisneros, J. Real-World Experience of Imipenem-Relebactam Treatment as Salvage Therapy in Difficult-to-Treat Pseudomonas aeruginosa Infections (IMRECOR Study). Infectious Diseases and Therapy. 2025; 14(1)DOI:10.1007/s40121-024-01077-z. PMID:39612160. IF:5.300(Q1/2D).
01/01/2025
Cefiderocol for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria (vol 13, 874, 2024)
Kirkegaard-Biosca, C, del Barrio-Tofiño, E, Villamarín, M, Larrosa, N, Campany, D, González-López, JJ, Ferrer, R, Viñado, B, Doménech, L, Sellarès-Nadal, J, Escolà-Vergé, L, Fernández-Hidalgo, N, Los-Arcos, I. Cefiderocol for the Treatment of Infections by VIM-Type-Producing Gram-Negative Bacteria (vol 13, 874, 2024). Antibiotics-Basel. 2025; 14(1)DOI:10.3390/antibiotics14010004. PMID:39858394. IF:4.600(Q1/2D).
01/01/2025
EULAR recommendations for the treatment of systemic sclerosis: 2023 update
Del Galdo, F, Lescoat, A, Conaghan, PG, Bertoldo, E, Colic, J, Santiago, T, Suliman, YA, Matucci-Cerinic, M, Gabrielli, A, Distler, O, Hoffmann-Vold, AM, Castellví, I, Balbir-Gurman, A, Vonk, M, Ananyeva, L, Rednic, S, Tarasova, A, Ostojic, P, Boyadzhieva, V, El Aoufy, K, Farrington, S, Galetti, I, Denton, CP, Kowal-Bielecka, O, Mueller-Ladner, U, Allanore, Y. EULAR recommendations for the treatment of systemic sclerosis: 2023 update. ANNALS OF THE RHEUMATIC DISEASES. 2025; 84(1)DOI:10.1136/ard-2024-226430. PMID:39874231. IF:20.600(Q1/1D).